4.6 Article

Dietary advanced glycation end-products (dAGEs) intake and its relation to sarcopenia and frailty - The Rotterdam Study

Journal

BONE
Volume 165, Issue -, Pages -

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.bone.2022.116564

Keywords

Diet; Advanced glycation end products; Sarcopenia; Frailty; Carboxymethyllysine

Funding

  1. Erasmus Medical Center
  2. Netherlands Organisation for Health Research and Development (ZonMw)
  3. Research Institute for Diseases in the Elderly (RIDE)
  4. Netherlands Genomics Initiative
  5. Ministry of Education, Culture and Science
  6. Netherlands the Ministry for Health, Welfare and Sports
  7. Erasmus University
  8. Municipality of Rotterdam, in the Netherlands
  9. Netherlands Organisation for Scientific Research (NWO)
  10. ZonMW [NWO/ZONMW-VIDI-016-136-367]
  11. Jaap Schouten Foundation, Rotterdam, The Netherlands
  12. European Commission (DG XII)

Ask authors/readers for more resources

A study investigated the relationship between dietary intake of carboxymethyllysine (dCML) and risk of sarcopenia and frailty. The researchers found an association between dAGEs and prevalent sarcopenia, but no association with incident sarcopenia or frailty.
Studies on mice have shown a relationship between dietary intake of advanced glycation end-products (dAGEs) and deterioration of musculoskeletal health, but human studies are absent. We investigated the relationship between dietary intake of carboxymethyllysine (dCML) - an AGE prototype - and risk of sarcopenia at baseline and after 5 years of follow-up and a single evaluation of physical frailty in participants from the population-based Rotterdam Study. Appendicular lean mass (ALM) was obtained using insight dual-energy X-ray absorptiometry and hand grip strength (HGS) using a hydraulic hand dynamometer. Subjects with both low ALM and weak HGS were classified as having sarcopenia. Frailty (yes/no) was defined by presence of >= 3 and pre-frailty by presence of 1 or 2 components namely, exhaustion, weakness, slowness, weight loss or low physical activity. dCML was calculated using a food frequency questionnaire and dAGE databases. Logistic regression analysis was used to evaluate the odds of physical frailty and prevalent sarcopenia at baseline and follow-up and incident sarcopenia. 2782 participants with an age 66.4 +/- 9.9 years and dCML intake 3.3 +/- 1.3 mg/day, had data on sarcopenia at both time points. Of whom 84 had sarcopenia at baseline and 73 developed sarcopenia at follow-up. We observed an association of one SD increase in dCML intake with prevalent sarcopenia at baseline [odds ratio, OR = 1.27 (1.01-1.59)] and no association of dCML with incident sarcopenia at 5-year follow-up [OR = 1.12 (0.86-1.44)]. For frailty we analyzed 3577 participants, of whom 1972 were pre-frail and 158 were frail. We observed no association of dCML with either pre-frailty [OR = 0.99 (0.91-1.07)] or frailty [OR = 1.01 (0.83-1.22)] when non-frail subjects were used as reference. Our results show an association of dAGEs with sarcopenia cross-sectionally but not longitudinally where inconclusive findings are observed possibly due to a very low incidence of sarcopenia. There was no association with frailty cross-sectionally.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available